@article{fdi:010078375,
  title = {{S}afety of high-dose ivermectin : a systematic review and meta-analysis},
  author = {{N}avarro, {M}. and {C}amprubi, {D}. and {R}equena-{M}endez, {A}. and {B}uonfrate, {D}. and {G}iorli, {G}. and {K}amgno, {J}. and {G}ardon, {J}acques and {B}oussinesq, {M}ichel and {M}unoz, {J}. and {K}rolewiecki, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {I}vermectin is a key anthelmintic for the control of neglected tropical diseases. {T}he main indications for population-{L}evel control with ivermectin through mass drug administration are onchocerciasis and {L}ymphatic filariasis; however, there is interest in using higher, fixed-dose regimens for the control of scabies, soil-transmitted helminths and malaria. {S}afety data for these higher-dose regimens are needed. {M}ethods: {A} systematic {L}iterature review and meta-analysis on the safety and doses of ivermectin was conducted. {E}ligible studies reported patient-{L}evel data and, for the meta-analysis, clinical trials reporting data on doses >= 200 and >= 400 mu g/kg were included. {I}ncidence ratios were used to compare adverse events by severity and organ system affected. {R}esults: {T}he systematic search identified six studies for inclusion, revealing no differences in the number of individuals experiencing adverse events. {A} descriptive analysis of these clinical trials for a variety of indications showed no difference in the severity of the adverse events between standard (up to 400 mu g/kg) and higher doses of ivermectin. {O}rgan system involvement only showed an increase in ocular events in the higher-dose group in one trial for the treatment of onchocerciasis, all of them transient and mild to moderate in intensity. {C}onclusions: {A}lthough within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses. {O}cular adverse events, despite being transient, are of concern in onchocerciasis patients. {T}hese data can inform programme managers and guide operational research activities as new approaches for the use of ivermectin are evaluated.},
  keywords = {},
  booktitle = {},
  journal = {{J}ournal of {A}ntimicrobial {C}hemotherapy},
  volume = {75},
  numero = {4},
  pages = {827--834},
  ISSN = {0305-7453},
  year = {2020},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078375},
}